Literature DB >> 23552412

A variant macaque-tropic human immunodeficiency virus type 1 is resistant to alpha interferon-induced restriction in pig-tailed macaque CD4+ T cells.

Rajesh Thippeshappa1, Hongmei Ruan, Weiming Wang, Paul Zhou, Jason T Kimata.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) antagonizes innate restriction factors in order to infect and persistently replicate in a host. In a previous study, we demonstrated that HIV-1 NL4-3 with a simian immunodeficiency virus mne (SIVmne) vif gene substitution (HSIV-vif-NL4-3) could infect and replicate in pig-tailed macaques (PTM), indicating that APOBEC3 proteins are primary barriers to transmission. Because viral replication was persistent but low, we hypothesized that HSIV-vif-NL4-3 may be suppressed by type I interferons (IFN-I), which are known to upregulate the expression of innate restriction factors. Here, we demonstrate that IFN-α more potently suppresses HSIV-vif-NL4-3 in PTM CD4(+) T cells than it does pathogenic SIVmne027. Importantly, we identify a variant (HSIV-vif-Yu2) that is resistant to IFN-α, indicating that the IFN-α-induced barrier can be overcome by HSIV-vif chimeras in PTM CD4(+) T cells. Interestingly, HSIV-vif-Yu2 and HSIV-vif-NL4-3 are similarly restricted by PTM BST2/Tetherin, and neither virus downregulates it from the surface of infected PTM CD4(+) T cells. Resistance to IFN-α-induced restriction appears to be conferred by a determinant in HSIV-vif-Yu2 that includes env su. Finally, we show that the Yu-2 env su allele may overcome an IFN-α-induced barrier to entry. Together, our data demonstrate that the prototype macaque-tropic HIV-1 clones based on NL4-3 may not sufficiently antagonize innate restriction in PTM cells. However, variants with resistance to IFN-α-induced restriction factors in PTM CD4(+) T cells may enhance viral replication by overcoming a barrier early in the viral replication cycle.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23552412      PMCID: PMC3676116          DOI: 10.1128/JVI.00338-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  121 in total

1.  Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques.

Authors:  Edward B Stephens; Coleen McCormick; Erik Pacyniak; Darcy Griffin; David M Pinson; Francis Sun; Warren Nothnick; Scott W Wong; Robert Gunderson; Nancy E J Berman; Dinesh K Singh
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

2.  Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.

Authors:  Caroline Goujon; Michael H Malim
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Interferon-alpha produces significant decreases in HIV load.

Authors:  Jorge A Tavel; Chiung-Yu Huang; Jean Shen; Julia A Metcalf; Robin Dewar; Akram Shah; M B Vasudevachari; Dean A Follmann; Betsey Herpin; Richard T Davey; Michael A Polis; Joseph Kovacs; Henry Masur; H Clifford Lane
Journal:  J Interferon Cytokine Res       Date:  2010-07       Impact factor: 2.607

4.  Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells.

Authors:  B F Fernie; G Poli; A S Fauci
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.

Authors:  Wendy W Yeh; Srinivas S Rao; So-Yon Lim; Jinrong Zhang; Peter T Hraber; Laura M Brassard; Corinne Luedemann; John Paul Todd; Alan Dodson; Ling Shen; Adam P Buzby; James B Whitney; Bette T Korber; Gary J Nabel; John R Mascola; Norman L Letvin
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

6.  The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR.

Authors:  S R Brand; R Kobayashi; M B Mathews
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

7.  Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.

Authors:  Cesar A Virgen; Zerina Kratovac; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

8.  HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation.

Authors:  Atsushi Okumura; Tim Alce; Barbora Lubyova; Heather Ezelle; Klaus Strebel; Paula M Pitha
Journal:  Virology       Date:  2007-12-20       Impact factor: 3.616

9.  HIV-1 infection in pigtailed macaques.

Authors:  S Gartner; Y Liu; M G Lewis; V Polonis; W R Elkins; P M Zack; J Miao; E A Hunter; J Greenhouse; G A Eddy
Journal:  AIDS Res Hum Retroviruses       Date:  1994       Impact factor: 2.205

10.  Evolution of a TRIM5-CypA splice isoform in old world monkeys.

Authors:  Ruchi M Newman; Laura Hall; Andrea Kirmaier; Lu-Ann Pozzi; Erez Pery; Michael Farzan; Shawn P O'Neil; Welkin Johnson
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823

View more
  12 in total

1.  The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy.

Authors:  Jing Zou; Wenjiao Li; Anisha Misra; Fei Yue; Kun Song; Qi Chen; Guanghua Guo; Jinglin Yi; Jason T Kimata; Leyuan Liu
Journal:  J Biol Chem       Date:  2015-01-28       Impact factor: 5.157

2.  Enhanced innate antiviral gene expression, IFN-α, and cytolytic responses are predictive of mucosal immune recovery during simian immunodeficiency virus infection.

Authors:  David Verhoeven; Michael D George; William Hu; Angeline T Dang; Zeljka Smit-McBride; Elizabeth Reay; Monica Macal; Anne Fenton; Sumathi Sankaran-Walters; Satya Dandekar
Journal:  J Immunol       Date:  2014-03-07       Impact factor: 5.422

Review 3.  Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

4.  Macaques as model hosts for studies of HIV-1 infection.

Authors:  Anisha Misra; Rajesh Thippeshappa; Jason T Kimata
Journal:  Front Microbiol       Date:  2013-06-28       Impact factor: 5.640

Review 5.  Stepping toward a macaque model of HIV-1 induced AIDS.

Authors:  Jason T Kimata
Journal:  Viruses       Date:  2014-09-25       Impact factor: 5.048

6.  Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-α Resistance.

Authors:  David F Boyd; Amit Sharma; Daryl Humes; Cecilia Cheng-Mayer; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2016-07-11       Impact factor: 6.823

7.  A single gp120 residue can affect HIV-1 tropism in macaques.

Authors:  Gregory Q Del Prete; Brandon F Keele; Jeannine Fode; Keyur Thummar; Adrienne E Swanstrom; Anthony Rodriguez; Alice Raymond; Jacob D Estes; Celia C LaBranche; David C Montefiori; Vineet N KewalRamani; Jeffrey D Lifson; Paul D Bieniasz; Theodora Hatziioannou
Journal:  PLoS Pathog       Date:  2017-09-25       Impact factor: 6.823

Review 8.  Toward a Macaque Model of HIV-1 Infection: Roadblocks, Progress, and Future Strategies.

Authors:  Rajesh Thippeshappa; Jason T Kimata; Deepak Kaushal
Journal:  Front Microbiol       Date:  2020-05-13       Impact factor: 5.640

9.  Host Restriction Factors APOBEC3G/3F and Other Interferon-Related Gene Expressions Affect Early HIV-1 Infection in Northern Pig-Tailed Macaque (Macaca leonina).

Authors:  Wei Pang; Jia-Hao Song; Ying Lu; Xiao-Liang Zhang; Hong-Yi Zheng; Jin Jiang; Yong-Tang Zheng
Journal:  Front Immunol       Date:  2018-08-28       Impact factor: 7.561

Review 10.  The role of BST-2/Tetherin in host protection and disease manifestation.

Authors:  Wadie D Mahauad-Fernandez; Chioma M Okeoma
Journal:  Immun Inflamm Dis       Date:  2015-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.